Kura Oncology, Inc.

Initiate a Phase 1/2 proof-of-concept study of tipifarnib with a PI3Kα inhibitor

Deadline passed; outcome being checked

Announced: 24 Feb 2021
Due: 31 Dec 2021
Status: Checking

Deadline
Met
Late
Not met
Today

What the company said

“Initiation of a Phase 1/2 proof-of-concept study of tipifarnib in combination with a PI3Kα inhibitor in the second half of 2021”

SourceKura Oncology, Inc. Form 8-K press release, 2021-02-24
FilingSEC filing index
Deadline as statedin the second half of 2021
Deadline used31 Dec 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-KURA-024364
Cite as https://keptindex.org/c/KI-C-2021-KURA-024364/ — this address never changes.

What we found

The deadline has passed. We check for public evidence starting 30 days after the deadline, and repeat the check if nothing clear turns up.

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical milestone
Indicative materiality: Medium rules
Action: Initiate
Deliverable: Phase 1/2 tipifarnib plus PI3Kα inhibitor study
In the company’s control: High
Specificity: High

Tell me what happens

This deadline has not been settled yet. We check 30 days after it passes. Get an email when we record the outcome.

Alert me when this resolves

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
OutcomeNot yet assessed. Nothing is judged before the deadline.

Are you Kura Oncology, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.

Report an error in this entry Reference: KI-C-2021-KURA-024364 · Corrections policy